Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

1st Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50937 Cologne, Germany.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.48). 09/2011; 55(12):5798-803. DOI: 10.1128/AAC.05134-11
Source: PubMed


Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥ 4 in 2 of 8 patients or ≥ 3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics were linear across the investigated dosages and followed a two-compartment model, with weight as the covariate on clearance and sex as the covariate on central volume of distribution. Simulated peak plasma concentrations at steady state ranged from 14.2 to 40.6 mg/liter (28%), trough concentrations from 4.1 to 11.8 mg/liter (58%), and area under the concentration-time curve from 175 to 500 mg/liter/h (32%) (geometric mean, geometric coefficient of variation). Treatment was well tolerated without dose-limiting toxicity. The rate of complete or partial responses was 54.3%, and the overall mortality at 12-week follow-up was 28.3%. In first-line treatment of invasive aspergillosis, daily doses of up to 200 mg caspofungin were well tolerated and the maximum tolerated dose was not reached. Pharmacokinetics was linear. Response rates were similar to those previously reported for voriconazole and liposomal amphotericin.

Download full-text


Available from: Jörg Janne Vehreschild, Feb 13, 2014
  • Source
    • "Echinocandin monotherapy might be an alternative , as the in vitro activity of echinocandins against A . fumigatus appear unaffected by the presence of an azole resistance mechanism ( van Ingen et al . , 2015 ) . Caspofungin has been shown to be efficacious for patients with IA ( Viscoli et al . , 2009 ; Herbrecht et al . , 2010 ; Cornely et al . , 2011 ) , but the success rates were disappointing with outcomes of 50% or less . One experimental study has shown comparable effec - tiveness of L - AmB against IA due to wild - type and azole - resistant Aspergillus , indicating that azole resistance does not diminish the efficacy of L - AmB ( Seyedmousavi et al . , 2013c ) . Thus , for azo"
    [Show abstract] [Hide abstract]
    ABSTRACT: An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro susceptibility testing should always be performed if antifungal therapy is intended. Different patterns of resistance are seen, with multi-azole and pan-azole resistance more common than resistance to a single triazole. In confirmed invasive pulmonary aspergillosis due to an azole-resistant Aspergillus, the experts recommended a switch from voriconazole to liposomal amphotericin B (L-AmB; Ambisome(®)). In regions with environmental resistance rates of ≥10%, a voriconazole-echinocandin combination or L-AmB were favoured as initial therapy. All experts recommended L-AmB as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and considered the addition of a second agent with the majority favouring flucytosine. Intravenous therapy with either micafungin or L-AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary aspergillosis due to a pan-azole-resistant Aspergillus. Local and national surveillance with identification of clinical and environmental resistance patterns, rapid diagnostics, better quality clinical outcome data, and a greater understanding of the factors driving or minimising environmental resistance are areas where research is urgently needed, as well as the development of new oral agents outside the azole drug class. Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
    Drug Resistance Updates 08/2015; 21-22. DOI:10.1016/j.drup.2015.08.001 · 9.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Trotz neuer antimykotischer Wirkstoffe, einer verbesserten Diagnostik, frühzeitiger Therapie und der Möglichkeit einer Kombinationsbehandlung stellen invasive Mykosen auf Grund ihrer hohen Inzidenz und infektions-assoziierten Letalität weiterhin eine besondere Gefahr für Patienten mit fortgeschrittener Immunsuppression dar. Eine spiegeladaptierte Therapie kann helfen toxische Nebenwirkungen zu reduzieren und die Effektivität einer Therapie zu steigern. Für Flucytosin und bestimmte Azole wird dies bereits in Leitlinien empfohlen. Nicht nur die Datenlage, sondern auch Möglichkeiten und Indikationen unterscheiden sich allerdings deutlich zwischen den Wirkstoffen. Die therapeutische Breite, intra- und interindividuelle Variabilität der bestimmten Konzentrationen und deren Korrelation mit dem Ansprechen sind wichtige Parameter für den Einsatz dieser Methode. So kann nicht für alle Substanzklassen eine Verbesserung des Ansprechens durch eine spiegelgestützte Therapie erwartet werden.
    Laboratoriums Medizin 03/2012; 36(2). DOI:10.1515/labmed-2011-0012 · 0.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Caspofungin, micafungin and anidulafungin are antifungal drugs with excellent safety profiles. Dosing regimens and treatment durations must be appropriate for optimal patient outcomes. Overall, factors that affect dosing of all three drugs are similar. Drug-specific properties, including in vitro concentration-dependent antifungal activity, activity against fungal biofilms, and pharmacokinetic and pharmacodynamic parameters influence dose selection and duration of therapy. Dosing strategies that provide “unbound” plasma drug concentrations exceeding the minimum inhibitory concentration (or minimum effective concentration) of the fungus are essential. Patient weight, age and illness severity are also important considerations for adequate exposure to drug: individuals >66 kg, pediatric patients and the critically-ill clear drug at higher rates although drug product information guidelines do not recommend for these populations to receive doses higher than those currently used. Clinical studies of treatment of, and prophylaxis against, Candida and Aspergillus infection indicate that currently recommended dosing regimens are adequate in most instances.
    Current Fungal Infection Reports 06/2012; 6(2). DOI:10.1007/s12281-012-0085-y
Show more